Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

H. Jean Khoury, Jorge Cortes, Michele Baccarani, Meir Wetzler, T. Masszi, Raghunadharao Digumarti, Adam Craig, Annie Claude Benichou, Luke Akard

Research output: Article

14 Citations (Scopus)

Abstract

Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice daily days 1-14 every 28 days until hematologic response/improvement or any cytogenetic response, then days 1-7 every 28 days until disease progression. The primary endpoint was maintenance or attainment of a major hematologic response (MHR). Cytogenetic responses were also evaluated. MHR was 37% in patients with AP-CML and 9% with BP-CML (22% and 5% in those with a history of T315I). Most grade 3/4 adverse events were related to myelosuppression, and were generally manageable. Omacetaxine demonstrates activity and an acceptable safety profile in pretreated patients with advanced CML, irrespective of mutational status.

Original languageEnglish
Pages (from-to)120-127
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number1
DOIs
Publication statusPublished - jan. 1 2015

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Cytogenetics
Leukemia, Myeloid, Accelerated Phase
Blast Crisis
Safety
Oncogene Proteins
homoharringtonine
Disease Progression
Maintenance
Apoptosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. / Khoury, H. Jean; Cortes, Jorge; Baccarani, Michele; Wetzler, Meir; Masszi, T.; Digumarti, Raghunadharao; Craig, Adam; Benichou, Annie Claude; Akard, Luke.

In: Leukemia and Lymphoma, Vol. 56, No. 1, 01.01.2015, p. 120-127.

Research output: Article

Khoury, H. Jean ; Cortes, Jorge ; Baccarani, Michele ; Wetzler, Meir ; Masszi, T. ; Digumarti, Raghunadharao ; Craig, Adam ; Benichou, Annie Claude ; Akard, Luke. / Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 1. pp. 120-127.
@article{0c71e81af8fa41fa93c92aaca4fba9a3,
title = "Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors",
abstract = "Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice daily days 1-14 every 28 days until hematologic response/improvement or any cytogenetic response, then days 1-7 every 28 days until disease progression. The primary endpoint was maintenance or attainment of a major hematologic response (MHR). Cytogenetic responses were also evaluated. MHR was 37{\%} in patients with AP-CML and 9{\%} with BP-CML (22{\%} and 5{\%} in those with a history of T315I). Most grade 3/4 adverse events were related to myelosuppression, and were generally manageable. Omacetaxine demonstrates activity and an acceptable safety profile in pretreated patients with advanced CML, irrespective of mutational status.",
keywords = "Accelerated, Blast, Drug resistance, Myeloid leukemias and dysplasias, Omacetaxine, Pharmacotherapeutics",
author = "Khoury, {H. Jean} and Jorge Cortes and Michele Baccarani and Meir Wetzler and T. Masszi and Raghunadharao Digumarti and Adam Craig and Benichou, {Annie Claude} and Luke Akard",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10428194.2014.889826",
language = "English",
volume = "56",
pages = "120--127",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

AU - Khoury, H. Jean

AU - Cortes, Jorge

AU - Baccarani, Michele

AU - Wetzler, Meir

AU - Masszi, T.

AU - Digumarti, Raghunadharao

AU - Craig, Adam

AU - Benichou, Annie Claude

AU - Akard, Luke

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice daily days 1-14 every 28 days until hematologic response/improvement or any cytogenetic response, then days 1-7 every 28 days until disease progression. The primary endpoint was maintenance or attainment of a major hematologic response (MHR). Cytogenetic responses were also evaluated. MHR was 37% in patients with AP-CML and 9% with BP-CML (22% and 5% in those with a history of T315I). Most grade 3/4 adverse events were related to myelosuppression, and were generally manageable. Omacetaxine demonstrates activity and an acceptable safety profile in pretreated patients with advanced CML, irrespective of mutational status.

AB - Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m2 twice daily days 1-14 every 28 days until hematologic response/improvement or any cytogenetic response, then days 1-7 every 28 days until disease progression. The primary endpoint was maintenance or attainment of a major hematologic response (MHR). Cytogenetic responses were also evaluated. MHR was 37% in patients with AP-CML and 9% with BP-CML (22% and 5% in those with a history of T315I). Most grade 3/4 adverse events were related to myelosuppression, and were generally manageable. Omacetaxine demonstrates activity and an acceptable safety profile in pretreated patients with advanced CML, irrespective of mutational status.

KW - Accelerated

KW - Blast

KW - Drug resistance

KW - Myeloid leukemias and dysplasias

KW - Omacetaxine

KW - Pharmacotherapeutics

UR - http://www.scopus.com/inward/record.url?scp=84922365628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922365628&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.889826

DO - 10.3109/10428194.2014.889826

M3 - Article

C2 - 24650054

AN - SCOPUS:84922365628

VL - 56

SP - 120

EP - 127

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -